Insight Partners, a global venture capital and private equity firm investing in high-growth technology and software companies, led a $20m Series A round in Trialjectory, an artificial intelligence-powered decision-support platform democratizing access to advanced cancer treatments, with participation from JAL Ventures, Contour Venture Partners, Rho Capital and TIA Ventures. "Trialjectory's use of machine learning enables a truly patient-centric approach to oncology. Our Computational Care thesis backs brave founders who unlock challenges affecting underserved patient populations with technology and empathy. Tzvia and TrialJectory work alongside the patient with empathy and machine learning to unearth better treatment options and accelerate more effective clinical trials," Scott Barclay, Insight Partners Managing Director.